Thursday 16 October, 2025
Introduction: Overall Survival (OS) is a gold standard clinical endpoint to assess efficacy of anticancer therapies. However, direct comparison of…
Read moreAbstracts
Longitudinal assessment of tumor size and neutrophil count in multivariate joint models are more predictive of survival than their baseline values in patients with non-small cell lung cancer
Thursday 16 October, 2025
Introduction: Tumor size, quantified by the Sum of Longest Diameters of target lesions (SLD), has been established as a prognostic…
Read moreNon-linear pharmacokinetics of eculizumab in atypical haemolytic uremic syndrome
Thursday 16 October, 2025
Objectives: Eculizumab is a monoclonal antibody targeting complement protein C5 approved in atypical haemolytic uremic syndrome (aHUS) with a dose…
Read moreMathematical modeling of RBC count dynamics after blood loss
Thursday 16 October, 2025
Introduction: The production of red blood cells (RBCs) in humans is an individual complex process. Our main interest lies in…
Read moreA Pharmacokinetic-Pharmacodynamic model built on in vitro data predict the antibacterial effect of polymyxin B against Klebsiella pneumoniae in vivo
Thursday 16 October, 2025
Introduction: Pharmacokinetic-Pharmacodynamic (PKPD) models built on preclinical data can be a useful tool for efficient exploration of antibiotic effects. Polymyxin B…
Read moreSimulation based assessment of different dosing strategies for anti-TNFα monoclonal antibodies in Crohn’s disease patients
Thursday 16 October, 2025
Introduction: Anti-tumour necrosis factor α (TNFα) monoclonal antibodies (mAbs) are a well-established treatment for patients with Crohn’s Disease (CD). However,…
Read moreTowards understanding anti-infliximab antibody development to predict Crohn’s disease patients’ underlying immunogenicity status
Thursday 16 October, 2025
Introduction: Inflammatory bowel diseases (IBD), including Crohn’s disease (CD), are a group of auto-immune diseases that affect the gastrointestinal tract….
Read moreQuantitative comparison of in vitro and in vivo variability of microdialysis experiments using nonlinear mixed-effects modelling on the example of linezolid
Thursday 16 October, 2025
Objectives: Developing and finding the optimal dosing regimen of antiinfectives with the goal of optimising therapeutic outcome and preventing the…
Read morePredicting the Fraction Unbound (fu) and Plasma Drug Clearance Based on Known Changes in Albumin and Alpha1-Acid Glycoprotein Levels at Varying Degrees of Renal Impairment
Thursday 16 October, 2025
Introduction/Objectives: Renal impairment (RI) leads to physiological changes that can affect the pharmacokinetics (PK) of drugs [1]. These changes, besides…
Read moreDiabetes progression modelling of competing risks of long-term complications and mortality using Swedish registry data
Thursday 16 October, 2025
Objectives: Type 2 diabetes mellitus (T2D) is a group of metabolic diseases that are associated with long-term damage to and…
Read more